Cambridge, UK, October 6, 2026

o2h Discovery is delighted to announce Neurovation Labs, Inc. as a recipient of the o2h Kickstarter Award. Neurovation Labs, a biotechnology company developing precision neurotherapeutics for central nervous system (CNS) disorders, is developing region-selective small molecules designed to modulate specific brain circuits, with its current programme focused on ionotropic glutamate receptor-mediated disorders, including Post-Traumatic Stress Disorder (PTSD).

The award will provide Neurovation Labs with access to o2h Discovery’s drug discovery and chemistry expertise as the company advances its precision neurotherapeutics programmes.

As part of the o2h Kickstarter Award, o2h Discovery will work alongside the Neurovation Labs team to provide chemistry and drug discovery support, complementing the company’s existing expertise in neuroscience, receptor biology and translational medicine.

The collaboration brings together Neurovation Labs’ focus on precision neurotherapeutics with o2h Discovery’s capabilities across small-molecule discovery, medicinal chemistry and integrated drug discovery.

Jennifer N. Perusini, Ph.D., Co-Founder & CEO, Neurovation Labs, said:

We are thrilled to receive the o2h Kickstarter Award, which is an exciting milestone for Neurovation Labs and a meaningful validation of our mission to develop precision neurotherapeutics. We are grateful to o2h for recognizing the potential of our approach to impact multiple CNS disorders with high unmet need and supporting us as we advance our program toward the clinic. Having o2h alongside us on this journey is a strategic opportunity as we work toward bringing a fundamentally new treatment approach to patients.

Sunil Shah, Co-CEO, o2h Discovery, said:

Reaching the 50th o2h Kickstarter Award is an important milestone for us and reflects our continued commitment to supporting emerging biotech companies as they advance their drug discovery programmes. Neurovation Labs is taking a focused approach to precision neurotherapeutics, combining its expertise in neuroscience and receptor biology to explore more targeted approaches to CNS disorders. We are pleased to support the Neurovation Labs team with our chemistry and drug discovery expertise as they continue to advance this promising programme.

Supporting Emerging Biotech Innovation

The o2h Kickstarter Award was established to support emerging biotechnology companies working on innovative drug discovery programmes by providing access to o2h Discovery’s chemistry expertise and drug discovery capabilities. programmes. 

Through the award, selected companies receive dedicated support designed to help address specific chemistry and discovery requirements at important stages of programme development.

Launched in 2022, the Kickstarter award has supported biotech companies across the UK, USA, Australia, Israel and Europe, helping 50 early-stage companies access specialist drug discovery capabilities as they work towards scientific, development and funding milestones. For more information, visit https://o2hdiscovery.co/o2h-kickstarter-north-america/ 

The selection of Neurovation Labs further expands the programme’s support for emerging companies developing new approaches to human health and drug discovery.

About Neurovation Labs, Inc.

Neurovation Labs is a preclinical-stage biotechnology company advancing a precision approach to mental health disorders. The company has developed a drug discovery platform based on an understanding of receptor biology, neuroscience and translational medicine and is using this platform to develop precision neuromodulators for CNS disorders.

Neurovation Labs is currently focused on a portfolio of region-selective small-molecule candidates for ionotropic glutamate receptor-mediated disorders. Its lead programme is focused on a small-molecule Negative Allosteric Modulator (NAM) of amygdala-specific AMPA receptors for the treatment of PTSD, with potential applications in aggression and impulsivity phenotypes. www.neurovationlabs.com

About o2h Discovery

Founded in 2005, o2h Discovery operates an insight-driven, multi-modality integrated drug discovery platform across Cambridge, UK and Ahmedabad, India. With expertise spanning medicinal chemistry, biology, DMPK, peptide discovery, scale-up chemistry and process development, o2h Discovery supports biotechnology and pharmaceutical companies from hit identification through lead optimisation and into IND-enabling studies. Through collaborative partnership models including o2h’s Kickstarter Award, o2h Discovery fast-tracks new ideas to a development candidate. For more information, visit: www.o2hdiscovery.co 

Media Contact

Mayank Gupta
Marketing Manager
o2h Discovery